Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 22, 2026, 2:42 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–16 of 16 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Mifepristone 300 MG Clear all
Completed Phase 3 Interventional Results available

An Extension Study of CORLUX in the Treatment of Endogenous Cushing's Syndrome

NCT00936741
View directory record Official record
Conditions
Cushing's Syndrome
Interventions
mifepristone
Drug
Lead sponsor
Corcept Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
15
States / cities
Birmingham, Alabama • Escondido, California • Stanford, California + 12 more
Source: ClinicalTrials.gov public record
Updated Apr 1, 2014 · Synced Sep 22, 2026, 2:42 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Short-Term Oral Mifepristone for Central Serous Chorioretinopathy

NCT02354170
View directory record Official record
Conditions
Central Serous Chorioretinopathy
Interventions
Mifepristone, Placebo
Drug
Lead sponsor
Roger Goldberg, M.D., MBA
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2017
U.S. locations
2
States / cities
Walnut Creek, California • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 25, 2017 · Synced Sep 22, 2026, 2:42 PM EDT
Recruiting Phase 2 Interventional

A Study of Enzalutamide, Enzalutamide in Combination With Mifepristone, or Chemotherapy in People With Metastatic Breast Cancer

NCT06099769
View directory record Official record
Conditions
Metastatic Breast Cancer
Interventions
Enzalutamide, Mifepristone, TPC
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
201 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
12
States / cities
Birmingham, Alabama • San Francisco, California • Chicago, Illinois + 9 more
Source: ClinicalTrials.gov public record
Updated Feb 24, 2026 · Synced Sep 22, 2026, 2:42 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Mifepristone Drug-Drug Interaction Study With CYP3A Inhibitor

NCT03259542
View directory record Official record
Conditions
Drug Interaction Potentiation, Healthy
Interventions
Mifepristone 300 MG, Itraconazole 100 MG
Drug
Lead sponsor
Corcept Therapeutics
Industry
Eligibility
18 Years to 65 Years · Male only
Enrollment
33 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Feb 21, 2018 · Synced Sep 22, 2026, 2:42 PM EDT
Active, not recruiting Phase 2 Interventional Results available

Abraxane® With or Without Mifepristone for Advanced, Glucocorticoid Receptor-Positive, Triple-Negative Breast Cancer

NCT02788981
View directory record Official record
Conditions
Breast Cancer
Interventions
Mifepristone, Placebo, Nab-Paclitaxel
Drug · Other
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2026
U.S. locations
5
States / cities
Birmingham, Alabama • Chicago, Illinois • Evanston, Illinois + 2 more
Source: ClinicalTrials.gov public record
Updated Jun 9, 2025 · Synced Sep 22, 2026, 2:42 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Crossover Drug-Drug Interaction Study to Determine Effects of Cytochrome P450 3A on Exposure to Mifepristone and Its Metabolites

NCT03258372
View directory record Official record
Conditions
Healthy
Interventions
Mifepristone
Drug
Lead sponsor
Corcept Therapeutics
Industry
Eligibility
18 Years to 65 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Feb 22, 2018 · Synced Sep 22, 2026, 2:42 PM EDT
Completed Phase 4 Interventional

Study to Determine the Prevalence of Hypercortisolism in Patients With Type 2 Diabetes and Treatment With Korlym® (Mifepristone) (CATALYST)

NCT05772169
View directory record Official record
Conditions
Hypercortisolism, Diabetes Mellitus, Type 2
Interventions
Mifepristone 300 MG [Korlym], Placebo for mifepristone
Drug
Lead sponsor
Corcept Therapeutics
Industry
Eligibility
18 Years to 80 Years
Enrollment
1,113 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
36
States / cities
Escondido, California • Gardena, California • Huntington Park, California + 29 more
Source: ClinicalTrials.gov public record
Updated Jan 19, 2025 · Synced Sep 22, 2026, 2:42 PM EDT
Terminated Phase 2 Interventional Results available

Efficacy of Mifepristone in Males With Type 2 Diabetes Mellitus

NCT03052400
View directory record Official record
Conditions
Type 2 Diabetes Mellitus, Insulin Resistance
Interventions
Mifepristone 600 mg daily, Placebo
Drug
Lead sponsor
Charles Drew University of Medicine and Science
Other
Eligibility
18 Years to 65 Years · Male only
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated May 17, 2023 · Synced Sep 22, 2026, 2:42 PM EDT
Not listed Phase 1 Interventional

Understanding GWI: Integrative Modeling

NCT04255498
View directory record Official record
Conditions
Gulf War Illness, Persian Gulf Syndrome, Occupational Diseases
Interventions
Etanercept, Mifepristone
Drug
Lead sponsor
South Florida Veterans Affairs Foundation for Research and Education
Federal
Eligibility
40 Years to 70 Years · Male only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Feb 4, 2020 · Synced Sep 22, 2026, 2:42 PM EDT
Terminated Phase 2 Interventional

Study of Oral Mifepristone as Salvage Therapy in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer

NCT02642939
View directory record Official record
Conditions
Non-Small Cell Lung Cancer (NSCLC)
Interventions
Mifepristone
Drug
Lead sponsor
Check, Jerome H., M.D., Ph.D.
Individual
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
1
States / cities
Melrose Park, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 18, 2020 · Synced Sep 22, 2026, 2:42 PM EDT
Completed Phase 3 Interventional

A United States Study of the Safety and Tolerability of Corlux for Psychotic Symptoms in Psychotic Major Depression

NCT00128479
View directory record Official record
Conditions
Major Depressive Disorder, Psychotic Disorders
Interventions
mifepristone, mifepristone matched placebo, mifepristone 600 mg, mifepristone 1200 mg
Drug
Lead sponsor
Corcept Therapeutics
Industry
Eligibility
18 Years to 75 Years
Enrollment
443 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
44
States / cities
Little Rock, Arkansas • Cerritos, California • Fountain Valley, California + 40 more
Source: ClinicalTrials.gov public record
Updated Feb 14, 2012 · Synced Sep 22, 2026, 2:42 PM EDT
Completed Phase 2 Interventional Results available

Mifepristone Treatment of Alcohol Use Disorder

NCT02179749
View directory record Official record
Conditions
Alcohol Dependence, Alcohol Use Disorders, Alcohol Abuse, Alcoholism
Interventions
Mifepristone 1200 mg daily, Standardized behavioral therapy, Placebo
Drug · Behavioral
Lead sponsor
The Scripps Research Institute
Other
Eligibility
18 Years to 65 Years
Enrollment
103 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Oct 5, 2022 · Synced Sep 22, 2026, 2:42 PM EDT
Completed Phase 2 Interventional Results available

Novel Therapeutics in Posttraumatic Stress Disorder (PTSD): A Randomized Clinical Trial of Mifepristone

NCT01739335
View directory record Official record
Conditions
Stress Disorders, Post-Traumatic
Interventions
Mifepristone Oral Tablet [Korlym], Placebo Oral Tablet
Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years to 89 Years · Male only
Enrollment
81 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
5
States / cities
San Diego, California • Albuquerque, New Mexico • The Bronx, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Jan 23, 2018 · Synced Sep 22, 2026, 2:42 PM EDT
Completed Phase 1 Interventional

Nab-paclitaxel (Abraxane) With or Without Mifepristone in Patients With Advanced Breast Cancer

NCT01493310
View directory record Official record
Conditions
Male Breast Cancer, Recurrent Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer
Interventions
mifepristone, placebo, nab-paclitaxel
Drug
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2018
U.S. locations
2
States / cities
Chicago, Illinois • Evanston, Illinois
Source: ClinicalTrials.gov public record
Updated Sep 11, 2018 · Synced Sep 22, 2026, 2:42 PM EDT
Completed Phase 1 Interventional

TNF and Glucocorticoid Antagonist for GWI Associated Multi-symptom Disease Homeostasis Reset

NCT04254627
View directory record Official record
Conditions
Gulf War Illness
Interventions
Etanercept, Mifepristone
Drug
Lead sponsor
Nova Southeastern University
Other
Eligibility
45 Years to 70 Years · Male only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
2
States / cities
Davie, Florida • Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jun 17, 2026 · Synced Sep 22, 2026, 2:42 PM EDT
Terminated Phase 3 Interventional Results available

A Study of Mifepristone vs. Placebo in the Treatment of Patients With Major Depression With Psychotic Features

NCT00637494
View directory record Official record
Conditions
Psychotic Depression, Severe Major Depression With Psychotic Features, Psychosis
Interventions
mifepristone, placebo
Drug
Lead sponsor
Corcept Therapeutics
Industry
Eligibility
22 Years and older
Enrollment
292 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2014
U.S. locations
42
States / cities
Little Rock, Arkansas • Anaheim, California • Downey, California + 34 more
Source: ClinicalTrials.gov public record
Updated Jun 4, 2017 · Synced Sep 22, 2026, 2:42 PM EDT